Biotech Values

[DewDiligence]

Xarelto—Looks like a CRL is coming next month and I don't know how long it will take to come up with the 'missing data' and if it's even possible without another clinical trial.

A possible remedy is to merge the NDA in ACS with the NDA in PCI, as was conjectured in #msg-75391993.

That plus not having Dr. Nissen on the next advisory panel might be enough to do the trick :- )

For now the 'nice call' goes to urche (#msg-69122895).

Agreed.